Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.59 |
| ▸ | BCHE | P06276 | 3/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059418 | 0.92 | BCHE (0.66) | ACHEBCHEMAOB | |
| SCHEMBL12043785 | 0.82 | ACHE (0.83) | ACHEBCHESIGMAR1 | |
| SCHEMBL7806519 | 0.81 | SIGMAR1 (0.63) | ACHEBCHESIGMAR1 | |
| SCHEMBL1554194 | 0.81 | TDP1 (0.61) | SIGMAR1 | |
| SCHEMBL3116231 | 0.80 | SIGMAR1 (0.56) | SIGMAR1LMNA | |
| SCHEMBL8782381 | 0.80 | — | — | |
| SCHEMBL1138416 | 0.78 | ACHE (0.76) | ACHEBCHE | |
| SCHEMBL7806521 | 0.78 | ACHE (0.71) | ACHEBCHE | |
| SCHEMBL13595611 | 0.77 | ATM (0.69) | LMNA | |
| SCHEMBL7853462 | 0.77 | ACHE (0.74) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0673927-B1 | piperidines as anticholinergic agents | EISAI CO LTD (JP) | 2001-09-19 | — | — | EP | claimed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| EP-0673927-B1 | piperidines as anticholinergic agents | EISAI CO LTD (JP) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ACHE 18/4885BCHE 42/4885SIGMAR1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.